rs2501431 — CNR2 CNR2 rs2501431

Synonymous coding variant in the cannabinoid receptor 2 gene that tags a haplotype block influencing CB2 receptor expression in immune cells; the G allele (coding-strand C) is associated with elevated rheumatoid arthritis risk and altered endocannabinoid-mediated immune regulation

See your personal result for CNR2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CNR2 rs2501431 — A Cannabinoid Receptor Variant at the Crossroads of Immune Control

The endocannabinoid system is best known for its role in the brain, but cannabinoid receptor 2 (CB2)11 cannabinoid receptor 2 (CB2)
CB2, encoded by the CNR2 gene on chromosome 1p36.11, is the peripheral cannabinoid receptor expressed predominantly on immune cells including macrophages, dendritic cells, B cells, and T cells rather than in the central nervous system. CB2 is a key gatekeeper of immune activity: when activated by endogenous ligands (2-AG, AEA) or exogenous cannabinoids, it generally suppresses inflammatory cytokine release, limits immune cell migration into inflamed tissue, and promotes resolution of inflammation. Genetic variation in CNR2 therefore influences how effectively this endogenous anti-inflammatory brake operates.

rs2501431 is a synonymous single-nucleotide variant in exon 4 of CNR2 (c.465C>T, Gly155=), meaning the amino acid sequence of the CB2 protein is unchanged. CNR2 lies on the minus strand, so the coding-strand notation C>T corresponds to G>A on the GRCh38 plus strand at chromosome 1, position 23,875,153. As a synonymous variant, rs2501431 likely acts as a tag SNP22 tag SNP
A tag SNP is a variant in linkage disequilibrium with nearby functional variants that it does not modify itself; it "tags" a haplotype block inherited together, and its statistical association with disease reflects the effect of those linked functional variants, marking a haplotype block in the CNR2 locus that may include regulatory variants affecting CB2 expression levels or mRNA stability.

The Mechanism

CB2 is highly expressed on macrophages in synovial tissue and on circulating lymphocytes. In rheumatoid arthritis, CB2 engages a complex signalling role: while CB2 agonism can suppress some inflammatory pathways, studies in RA synovial fibroblasts show that CB2 can also amplify IL-1β-driven inflammation through TAK1 (TGF-β-activated kinase 1) — NF-κB — AP-1 signalling33 TAK1 (TGF-β-activated kinase 1) — NF-κB — AP-1 signalling
TAK1 is a central kinase in inflammatory signalling cascades; its activation drives NF-κB into the nucleus to transcribe inflammatory genes including IL-6, IL-8, and matrix metalloproteinases that degrade cartilage and bone. CB2 expression is substantially elevated in synovial tissue from RA joints compared with osteoarthritis joints, consistent with a role in sustaining synovial inflammation.

The rs2501431 G allele (plus strand) tags a haplotype where this CB2-mediated inflammatory amplification may be enhanced — perhaps through higher CNR2 expression in immune cells, altered CB2 coupling efficiency, or LD with an upstream regulatory variant. The precise causal variant within this haplotype block has not been identified, but the association with rheumatoid arthritis risk is statistically robust in the Lebanese cohort (PMID 38498014).

The Evidence

The strongest autoimmune association comes from a 2024 case-control study44 2024 case-control study
Ismail & Khawaja, Cannabis and Cannabinoid Research 9(6): e1597–e1603; 2024 in Lebanese RA patients versus healthy controls. Individuals homozygous for the G allele (coding CC genotype) had more than a 13-fold increased risk of developing rheumatoid arthritis compared with homozygous A individuals (coding TT), and the G allele (coding C allele) was present at 64% frequency in RA patients. This is a substantial effect size that places rs2501431 among the CNR2 variants warranting attention in autoimmune genetics.

The mechanistic underpinning comes from in vitro work in RA synovial fibroblasts: CB2 knockdown55 CB2 knockdown
Fechtner et al., Clin Exp Rheumatol 2019, PMID 30943136 reduced IL-1β-induced production of IL-6, IL-8, ENA-78, and RANTES by more than 50%, while CB2 stimulation enhanced pro-inflammatory NF-κB and AP-1 activation via TAK1. Separate work66 Separate work
Fukuda et al., BMC Musculoskelet Disord 2014, PMID 25115332 confirmed that CB2 is markedly overexpressed in rheumatoid synovial tissue versus osteoarthritic controls, supporting a disease-amplifying rather than purely protective role in the RA joint.

Several studies from East Asian cohorts have also associated rs2501431 with bone mineral density (BMD)77 bone mineral density (BMD)
Zhang et al., Osteoporos Int 2015, PMID 26055357; Woo et al., Menopause 2015, PMID 25268406, but with inconsistent directionality across studies — some showing the A homozygote (coding TT) associated with lower lumbar BMD, others showing the G allele (coding C) associated with osteoporosis risk. This inconsistency likely reflects different LD patterns between the Lebanese and East Asian populations, confirming that rs2501431 is acting as a tag SNP rather than as a causal variant itself.

The evidence base is moderate in strength: the RA association comes from a single study (PMID 38498014) with a striking effect size but requiring independent replication in additional cohorts, and the BMD associations are replicated but discordant in direction. The mechanistic data on CB2's role in RA pathophysiology is solid.

Practical Actions

Carriers of two G alleles (GG) face the strongest signal for RA risk at this locus. This warrants proactive joint monitoring — tracking early symptoms such as morning stiffness, symmetric joint swelling, and elevated CRP or ESR — and awareness that the CB2/endocannabinoid system is an active research target for RA therapy. CB2-selective agonists are in early-phase development for inflammatory joint disease; this genetic context may become clinically relevant as those therapies progress.

Diet-wise, omega-3 fatty acids (EPA and DHA) directly activate the endocannabinoid system's resolution arm and reduce synovial inflammation independently of CB2 genotype, but they are especially relevant here given the CB2 pathway's central role in resolving inflammation.

Interactions

rs2501431 lies in the CNR2 gene on chromosome 1p36. The CNR2 Q63R variant (rs35761398, c.188A>G, p.Gln63Arg) is the most studied functional CNR2 polymorphism and is associated with multiple sclerosis, juvenile idiopathic arthritis, and celiac disease in separate studies. The two variants are in different functional contexts (Q63R is a missense change; rs2501431 is synonymous) and appear to tag different aspects of CNR2 biology. Combined effects of these two variants within CNR2 have not been formally studied. The CNR1 variant rs1049353 in the related cannabinoid receptor 1 gene provides orthogonal endocannabinoid system context.

Genotype Interpretations

What each possible genotype means for this variant.

AA Common Genotype Normal

Common CNR2 genotype — standard CB2-mediated immune tone

You carry two copies of the A allele (plus strand) at rs2501431, corresponding to the TT genotype in coding-strand notation. This is the most common genotype globally, carried by approximately 35% of the world population under Hardy-Weinberg equilibrium, and is the reference genotype in the rheumatoid arthritis association study. The A allele is more frequent in African (77%) and South Asian (72%) ancestries and somewhat common in European and East Asian populations (~57%). At this locus, your CB2-mediated inflammatory tone is at the population baseline, without the elevated RA susceptibility signal associated with the G allele.

AG Heterozygous Carrier Intermediate

One copy of the RA-associated G allele — mildly elevated inflammatory signal at this CNR2 locus

You carry one copy of the G allele (plus strand) at rs2501431, corresponding to the CT genotype in coding-strand notation. This heterozygous genotype is the most common globally (approximately 48% under Hardy-Weinberg equilibrium). The RA association study in Lebanese patients found the G allele was substantially enriched in cases, and heterozygous carriers are expected to carry an intermediate level of risk compared with GG and AA homozygotes, consistent with a codominant pattern. The evidence for this intermediate risk is inferred from the allelic association rather than directly measured for the AG genotype specifically.

GG High-Risk Genotype High Risk

Two copies of the RA-associated G allele — substantially elevated rheumatoid arthritis risk signal at this CNR2 locus

You carry two copies of the G allele (plus strand) at rs2501431, corresponding to the CC genotype in coding-strand notation. This genotype was found at 47.6% frequency in Lebanese rheumatoid arthritis patients and was associated with more than 13-fold increased risk of developing RA compared with the AA genotype. Globally, approximately 17% of people carry this GG genotype (Hardy-Weinberg estimate from gnomAD). This is a substantial risk signal at a single locus; RA is a polygenic and multifactorial disease, but a >13-fold odds ratio is among the larger effect sizes reported for common variants in complex autoimmune conditions. The variant is synonymous and acts as a tag for a risk haplotype in the CNR2 locus — the exact causal mechanism awaits identification, but the CB2 receptor's documented role in amplifying IL-1β-driven NF-κB signalling in RA synovial fibroblasts provides a plausible biological pathway.